121 related articles for article (PubMed ID: 27098621)
1. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
[TBL] [Abstract][Full Text] [Related]
2. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.
Sithambaram S; Hilmi I; Goh KL
PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845
[TBL] [Abstract][Full Text] [Related]
3. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
5. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
7. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
9. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
11. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
Tonus C; Neupert G; Sellinger M
World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
[TBL] [Abstract][Full Text] [Related]
13. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
14. The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study.
Che Alhadi S; Wan Zain WZ; Zahari Z; Md Hashim MN; Syed Abd Aziz SH; Zakaria Z; Wong MP; Zakaria AD
Ann Coloproctol; 2020 Dec; 36(6):409-414. PubMed ID: 32972105
[TBL] [Abstract][Full Text] [Related]
15. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
Hardt PD; Ewald N
Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
Li Y; Wang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
[TBL] [Abstract][Full Text] [Related]
18. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
19. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
20. Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps.
Rigi F; Jannatabad A; Izanloo A; Roshanravan R; Hashemian HR; Kerachian MA
BMC Gastroenterol; 2020 Jul; 20(1):241. PubMed ID: 32727566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
